New: NCI-funded clinical trial search
Mednet Logo
CommunityPediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

Do you offer fertility preservation to patients prior to CAR-T therapy?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Phoenix Children's Medical Group

There is no evidence yet about the impact of CAR-T itself on fertility, and this will be difficult to study in isolation in this population. Many CAR-T patients have been heavily pre-treated, so semen cryopreservation and oocyte harvesting may not be successful; but if feasible they should be attemp...

How do you decide the right time to transition to hospice?

8
4 Answers

Mednet MemberInvited Expert
Medical Oncology · Stanford University School of Medicine

Talking about hospice is one of the hardest jobs we have. It's hard because we don't like doing it, because we often don't know how to do it well, and because we angst about doing it too early or too late. It's an important thing to think about. I actually think perhaps the most important factor in ...

Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?

3 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Case Western Reserve University School of Medicine

COVID-19 disease in children seems to be less severe than adults based on the current literature and our personal experience at Children's Hospitals. Among adults, the coagulopathy is beginning to be described with elevated inflammatory markers and other markers of coagulation activation, including ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How should dose homogeneity across bone be handled in pediatric patients?

5
2 Answers

Mednet MemberInvited Expert
Radiation Oncology · University of Nebraska Medical Center

The radiation-associated bone damage can be affected by many factors, including total radiation dose, fractionation schedule, treatment volume, age of the child, symmetry of the delivered dose over vertebrae, developmental status of the irradiated growth plates, treatments such as chemotherapy or su...

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center

The management of advanced cancer patients has gotten even more complex with the COVID-19 pandemic. In general, providers are trying to keep patients away from the hospital/clinic as much as possible, and avoiding regimens with greater toxicity if there are suitable less toxic alternatives. Whether ...

Is dexrazoxane recommended for cardioprotection in AYA patients with Hodgkin lymphoma who are receiving anthracyclines as part of their upfront therapy?

3 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Children's Hospital Los Angeles

This is a good question that reflects the growing body of evidence in favor of dexrazoxane cardioprotection being safe and beneficial (Chow et al., PMID 26014292; Getz et al., PMID 32343641). For AYAs with Hodgkin lymphoma, doxorubicin remains a key component of therapy even for lower stage disease ...

How do you choose first or second-line systemic therapy for fibrolamellar hepatocellular carcinoma?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center

Fibrolamellar carcinoma is histologically unique from hepatocellular carcinoma. The disease is correctly called fibrolamellar carcinoma, and not fibrolamellar hepatocellular carcinoma, or hepatocellular carcinoma fibrolamellar variant. Even though the latter may be permissive if the lack of cirrhosi...

How do you approach immediate management of paraspinal extramedullary hematopoiesis in patients with transfusion-dependent thalassemia when lesions are enlarging or causing neurologic symptoms?

1
1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

In general, the goal of transfusion therapy in transfusion-dependent thalassemia (TDT) is to suppress ineffective erythropoiesis. It is the rationale for maintaining a higher pre-transfusion hemoglobin level, at 9.5-10.5 g/dl, well above the general threshold for PRBC transfusion used in oncology pa...

What is your response to the question, "Is this terminal?"

18
8 Answers

Mednet MemberInvited Expert
Medical Oncology · Stanford University School of Medicine

Thanks for this question, it's really important. This question comes up in two distinct scenarios: when a person is first diagnosed and when a person is nearing the end of her life. Let's talk about them in sequence. 1). At diagnosis: When a person is first diagnosed, this question is part of "getti...

Can an AYA patient with newly diagnosed AML safely sperm bank after starting cytoreduction with hydroxyurea or cytarabine?

2 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Children’s National Hospital

Thanks for the question. Unfortunately, there is not a lot of data available to answer this question with certainty. Because of that, I err on the side of saying that this should not be done. The concern lies with the possible impact on the sperm DNA, and the subsequent effect that might have on a p...